Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Ven...( FORT WORTH Texas July 30 /- Wound...),Health

FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen product, CellerateRx(R), on diabetic venous ulcers. "According to data released by the Centers for Disease Control and Prevention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations. Venous stasis ulcers of the lower extremity is a common problem among diabetic patients and presents significant quality of life issues for them as well as tremendous costs to the healthcare system. It has been estimated that venous ulcers cause the loss of approximately 2 million working days and incur treatment costs of approximately $3 billion per year in the United States.(1) "We have had very positive feedback from clinicians using CellerateRx(R) on these types of wounds. We look forward to providing this data to the medical community," Bradshaw said.

(1) New England Journal of Medicine, Bergan et al

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (WNDM), Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information visit http://www.Celleraterx.com .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this
'/>"/>